Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 113
interventional 91
Observational 19
Registry 3

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 43
Drug|placebo 19
Device 12
Other 4
Biological 3
Behavioral|Drug 2
Device|Other 2
Behavioral|Drug|placebo 1
Behavioral|Other 1
Biological|Genetic 1
Device|placebo 1
Drug|Other 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 57
France 4
Australia 3
Brazil 3
Canada 3
NA 3
Spain 3
United States|Canada 3
Austria 2
Denmark 2
United States|Puerto Rico 2
China 1
Portugal 1
United Kingdom 1
United States|Belgium|Brazil|Canada|Germany|Greece|Israel|Italy|Netherlands|Portugal|Russian Federation|Spain|Turkey|United Kingdom 1
United States|Belgium|Canada|France|Spain|United Kingdom 1
United States|Canada|France|Germany|Italy|Mexico|Poland|Spain|United Kingdom 1

Sites per Study

Site_count Study_Count
1 64
2 3
3 4
4 2
5 2
6 1
7 2
10 1
11 2
25 1
28 1
30 1
31 3
34 1
42 1
49 1
58 1

Phase

Phase Study_Count
N/A 31
Phase 2 21
Phase 4 18
Phase 3 8
Phase 1 7
Phase 2/Phase 3 3
Phase 1/Phase 2 2
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 26
2 34
3 9
4 2
5 2
8 1
NA 17

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 160 2.00 6.0 5 4.00000 25.0 30.00 10.00000
1st Qu. 160 13.25 16.0 23 11.00000 42.5 83.75 24.00000
Median 160 35.50 18.0 41 23.00000 60.0 205.50 50.00000
Mean 160 44.90 24.0 41 47.33333 84.0 243.00 64.94118
3rd Qu. 160 55.75 27.5 59 50.00000 113.5 347.50 88.00000
Max. 160 221.00 56.0 77 342.00000 167.0 630.00 219.00000

Trial Group Type

group_type Group_Count
Experimental 80
Active Comparator 32
Placebo Comparator 22
NA 17
Other 9
No Intervention 2
Sham Comparator 2

Intervention Model

intervention_model Study_Count
Parallel Assignment 44
Single Group Assignment 28
NA 9
Crossover Assignment 5
Factorial Assignment 3
Sequential Assignment 2

Primary Purpose

primary_purpose Study_Count
Treatment 74
Diagnostic 6
Prevention 5
Other 3
Basic Science 1
Health Services Research 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
United States 11
France 2
NA 2
United States|Puerto Rico 2
Germany 1
Spain 1

Sites per Study

Site_count Study_Count
1 15
3 1
4 1
5 1
38 1

Enrollment Metrics

Measure Observational
Min 8.0000
1st Qu 31.0000
Median 60.0000
Mean 126.3684
3rd Qu 155.5000
Max 500.0000

Observation Model

observational_model Study_Count
Cohort 10
NA 5
Case-Only 2
Case Control 2

Time Perspective

time_perspective Study_Count
Prospective 9
Cross-Sectional 5
NA 5

Registries

Studies by Country

Country Study_Count
United States 2
France|Germany|Italy|Netherlands|Poland|Portugal|Russian Federation|Spain|Turkey|United Kingdom 1

Sites per Study

Site_count Study_Count
1 2
17 1

Enrollment Metrics

Measure Registries
Min 257.0
1st Qu 378.5
Median 500.0
Mean 1919.0
3rd Qu 2750.0
Max 5000.0

Registry Model

observational_model Study_Count
Cohort 2
Case-Only 1

Time Perspective

time_perspective Study_Count
Prospective 2
Cross-Sectional 1

Follow-up

target_duration Study_Count
4 Years 1
5 Years 1
50 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03407313 CONFORM: Rotational Fractional Resection for Submental Contouring https://ClinicalTrials.gov/show/NCT03407313 Completed Recros Medica, Inc. 2018-12-28
NCT03936829 Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes https://ClinicalTrials.gov/show/NCT03936829 Recruiting Children’s Hospital of Fudan University 2021-05-31
NCT03275259 Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat https://ClinicalTrials.gov/show/NCT03275259 Completed Indústria Brasileira Equipamentos Médicos - IBRAMED 2018-01-01
NCT03226821 Body Composition and Adipose Tissue in HIV https://ClinicalTrials.gov/show/NCT03226821 Recruiting Columbia University 2021-04-30
NCT03075332 Detraining in People Living With HIV/AIDS https://ClinicalTrials.gov/show/NCT03075332 Completed Universidade Federal do Rio Grande do Norte 2016-06-21
NCT03050749 Safety and Performance of Princess® VOLUME for the Treatment of Facial Lipoatrophy, Asymmetry or Scars https://ClinicalTrials.gov/show/NCT03050749 Completed Croma-Pharma GmbH 2017-10-18
NCT03050723 Safety and Performance of Princess® FILLER for the Treatment of Facial Lipoatrophy, Asymmetry or Scars https://ClinicalTrials.gov/show/NCT03050723 Completed Croma-Pharma GmbH 2017-07-17
NCT03039491 Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults https://ClinicalTrials.gov/show/NCT03039491 Completed Medical University of South Carolina 2020-03-30
NCT02914886 Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) https://ClinicalTrials.gov/show/NCT02914886 Completed Kinderkrankenhaus auf der Bult 2019-04-30
NCT02858830 Familial Partial Lipodystrophy Study https://ClinicalTrials.gov/show/NCT02858830 Active, not recruiting Mayo Clinic 2018-02-28
NCT02743403 Effects of TENS in Pain During Application of Carboxytherapy in Patients With Gynoid Lipodystrophy https://ClinicalTrials.gov/show/NCT02743403 Completed Universidade Cidade de Sao Paulo 2016-04-30
NCT02684591 Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy https://ClinicalTrials.gov/show/NCT02684591 Completed University of California, San Diego 2018-02-28
NCT02654977 CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy https://ClinicalTrials.gov/show/NCT02654977 Active, not recruiting University of Michigan 2020-02-29
NCT02647853 Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers https://ClinicalTrials.gov/show/NCT02647853 Completed Topokine Therapeutics, Inc. 2014-12-31
NCT02639286 Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension https://ClinicalTrials.gov/show/NCT02639286 Completed National Institutes of Health Clinical Center (CC) 2019-09-26
NCT02527343 The BROADEN Study: A Study of Volanesorsen (Formerly ISIS-APOCIIIRx) in Patients With Familial Partial Lipodystrophy https://ClinicalTrials.gov/show/NCT02527343 Active, not recruiting Ionis Pharmaceuticals, Inc. 2018-06-30
NCT02492997 Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference https://ClinicalTrials.gov/show/NCT02492997 Completed Venus Concept 2016-10-31
NCT02430077 Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients https://ClinicalTrials.gov/show/NCT02430077 Recruiting University of Texas Southwestern Medical Center 2020-09-30
NCT02404896 Expanded Access Metreleptin Study https://ClinicalTrials.gov/show/NCT02404896 Active, not recruiting University of Michigan 2025-01-31
NCT02342223 Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy https://ClinicalTrials.gov/show/NCT02342223 Completed VA Northern California Health Care System 2016-05-31
NCT02262832 Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy https://ClinicalTrials.gov/show/NCT02262832 Recruiting National Institutes of Health Clinical Center (CC) 2025-07-31
NCT02262806 Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy https://ClinicalTrials.gov/show/NCT02262806 Recruiting National Institutes of Health Clinical Center (CC) 2025-07-31
NCT02056912 Identification of a New Gene Involved in Hereditary Lipodystrophy https://ClinicalTrials.gov/show/NCT02056912 Completed University Hospital, Bordeaux 2014-01-31
NCT01778556 Short-term Effects of Leptin in People With Lipodystrophy https://ClinicalTrials.gov/show/NCT01778556 Completed National Institutes of Health Clinical Center (CC) 2018-02-23
NCT01679197 Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy https://ClinicalTrials.gov/show/NCT01679197 Completed University of Michigan 2016-07-13
NCT01671839 Study of the Cabochon System for Improvement in the Appearance of Cellulite https://ClinicalTrials.gov/show/NCT01671839 Completed Merz North America, Inc. 2013-09-30
NCT01612858 Metabolic Abnormalities in HIV-infected Persons https://ClinicalTrials.gov/show/NCT01612858 Completed Tufts Medical Center 2014-11-30
NCT01511016 Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome https://ClinicalTrials.gov/show/NCT01511016 Completed Baylor College of Medicine 2011-06-30
NCT04159415 Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy https://ClinicalTrials.gov/show/NCT04159415 Active, not recruiting Regeneron Pharmaceuticals 2021-05-31
NCT04026178 Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy https://ClinicalTrials.gov/show/NCT04026178 Recruiting Aegerion Pharmaceuticals, Inc. 2022-01-31
NCT03986983 Shockwave Therapy (SWT) https://ClinicalTrials.gov/show/NCT03986983 Completed Escola Superior de Tecnologia da Saúde do Porto 2019-07-26
NCT03966924 The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring https://ClinicalTrials.gov/show/NCT03966924 Completed Recros Medica, Inc. 2019-10-16
NCT03514420 Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With With Familial Partial Lipodystrophy (FPL) https://ClinicalTrials.gov/show/NCT03514420 Completed Akcea Therapeutics 2019-07-30
NCT03508687 Study of Gemcabene in Adults With FPLD https://ClinicalTrials.gov/show/NCT03508687 Completed University of Michigan 2019-07-31
NCT03445351 Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS https://ClinicalTrials.gov/show/NCT03445351 Completed Universidade Federal do Rio Grande do Norte 2015-04-22
NCT01263717 Effects of Growth Hormone Releasing Hormone in HIV https://ClinicalTrials.gov/show/NCT01263717 Completed Massachusetts General Hospital 2014-02-28
NCT01077765 Polyacrylamide Hydrogel Injection in HIV-related Lipoatrophy https://ClinicalTrials.gov/show/NCT01077765 Completed Assistance Publique - Hôpitaux de Paris 2008-07-31
NCT01023620 HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone) https://ClinicalTrials.gov/show/NCT01023620 Completed University of Texas Southwestern Medical Center 2010-05-31
NCT00978237 Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients https://ClinicalTrials.gov/show/NCT00978237 Completed Hospital Clinic of Barcelona 2013-11-30
NCT00931268 Morphological and Functional Evaluation of Buttock Lipoatrophy Treatment With Macrolane https://ClinicalTrials.gov/show/NCT00931268 Completed Q-Med AB 2011-09-30
NCT00896298 Trial of Leptin Replacement Therapy in Patients With Lipodystrophy https://ClinicalTrials.gov/show/NCT00896298 Completed University of Texas Southwestern Medical Center 2014-11-30
NCT00865007 Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy https://ClinicalTrials.gov/show/NCT00865007 Completed Fundacion SEIMC-GESIDA 2012-06-30
NCT02009462 Artefill for the Treatment of HIV-associated Facial Lipoatrophy https://ClinicalTrials.gov/show/NCT02009462 Active, not recruiting AIDS Research and Treatment Center of the Treasure Coast 2019-11-30
NCT01828723 Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells https://ClinicalTrials.gov/show/NCT01828723 Completed Antria 2015-01-31
NCT01848340 An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects https://ClinicalTrials.gov/show/NCT01848340 Completed ViiV Healthcare 2013-07-31
NCT00677313 An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy https://ClinicalTrials.gov/show/NCT00677313 Completed Bristol-Myers Squibb 2015-01-31
NCT00656851 Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome https://ClinicalTrials.gov/show/NCT00656851 Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2009-08-31
NCT00656175 Raltegravir Therapy for Women With HIV and Fat Accumulation https://ClinicalTrials.gov/show/NCT00656175 Completed University of California, Los Angeles 2011-12-31
NCT00647946 Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue https://ClinicalTrials.gov/show/NCT00647946 Completed Gilead Sciences 2004-10-31
NCT00646984 Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy https://ClinicalTrials.gov/show/NCT00646984 Completed Hospital Clinic of Barcelona 2005-04-30
NCT00639457 Exercise and Pioglitazone for HIV-Metabolic Syndromes https://ClinicalTrials.gov/show/NCT00639457 Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2008-12-31
NCT00627380 Yoga for the Management of HIV-Metabolic Syndromes https://ClinicalTrials.gov/show/NCT00627380 Completed Washington University School of Medicine 2009-06-30
NCT00608023 TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy https://ClinicalTrials.gov/show/NCT00608023 Completed Theratechnologies 2008-10-31
NCT00585715 Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening https://ClinicalTrials.gov/show/NCT00585715 Completed University of California, Irvine 2009-12-31
NCT00461552 Therapeutic Approaches to HAART-Induced Lipodystrophy https://ClinicalTrials.gov/show/NCT00461552 Completed University of Texas Southwestern Medical Center 2014-09-30
NCT00457938 Novel Therapies for Metabolic Complications of Lipodystrophies https://ClinicalTrials.gov/show/NCT00457938 Completed University of Texas Southwestern Medical Center 2014-11-30
NCT00457665 Mechanisms of Lipodystrophy in HIV-Infected Pateints https://ClinicalTrials.gov/show/NCT00457665 Completed University of Texas Southwestern Medical Center 2007-10-31
NCT00457639 Cholic Acid for Hepatic Steatosis in Lipodystrophy https://ClinicalTrials.gov/show/NCT00457639 Completed University of Texas Southwestern Medical Center 2011-04-30
NCT00383734 Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE https://ClinicalTrials.gov/show/NCT00383734 Completed French National Agency for Research on AIDS and Viral Hepatitis 2008-09-30
NCT00367744 Rosiglitazone Effect on Mitochondria and Lipoatrophy https://ClinicalTrials.gov/show/NCT00367744 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2008-12-31
NCT00362440 Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome https://ClinicalTrials.gov/show/NCT00362440 Completed Beth Israel Deaconess Medical Center 2011-05-31
NCT00333684 Safety, Efficacy and Psychological Effects of Treating Antiretroviral Drug-Induced Facial Lipoatrophy With Bio-Alcamid https://ClinicalTrials.gov/show/NCT00333684 Completed Canadian Immunodeficiency Research Collaborative 2006-11-30
NCT00312832 Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00312832 Completed Hospital Clinic of Barcelona NA
NCT00307164 Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy https://ClinicalTrials.gov/show/NCT00307164 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2008-12-31
NCT00246376 Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia https://ClinicalTrials.gov/show/NCT00246376 Completed Baylor College of Medicine 2009-09-30
NCT00227500 Pravastatin for Hyperlipidaemia in HIV. https://ClinicalTrials.gov/show/NCT00227500 Completed Kirby Institute NA
NCT00202241 The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS https://ClinicalTrials.gov/show/NCT00202241 Completed Queen’s University NA
NCT00202228 Lactate Metabolism Study in HIV Infected Persons https://ClinicalTrials.gov/show/NCT00202228 Completed Queen’s University 2008-10-31
NCT00192660 HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) https://ClinicalTrials.gov/show/NCT00192660 Completed Kirby Institute 2006-10-31
NCT00192621 Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects https://ClinicalTrials.gov/show/NCT00192621 Completed Kirby Institute 2006-12-31
NCT00140244 Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome https://ClinicalTrials.gov/show/NCT00140244 Completed Beth Israel Deaconess Medical Center 2011-06-30
NCT00139178 Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. https://ClinicalTrials.gov/show/NCT00139178 Completed Danish HIV Research Group NA
NCT00135356 Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome https://ClinicalTrials.gov/show/NCT00135356 Completed Bristol-Myers Squibb 2007-07-31
NCT00130286 Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance https://ClinicalTrials.gov/show/NCT00130286 Completed Weill Medical College of Cornell University 2010-08-31
NCT00123253 TH9507 in Patients With HIV-Associated Lipodystrophy https://ClinicalTrials.gov/show/NCT00123253 Completed Theratechnologies 2006-11-30
NCT00119769 The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients https://ClinicalTrials.gov/show/NCT00119769 Completed Hvidovre University Hospital 2007-05-31
NCT00119379 Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults https://ClinicalTrials.gov/show/NCT00119379 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2008-10-31
NCT00100698 Physiologic Growth Hormone Effects in HIV Lipodystrophy https://ClinicalTrials.gov/show/NCT00100698 Completed Massachusetts General Hospital 2007-10-31
NCT00082628 Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients https://ClinicalTrials.gov/show/NCT00082628 Completed EMD Serono 2005-09-28
NCT00795210 Effects of Short-term Growth Hormone in HIV-infected Patients https://ClinicalTrials.gov/show/NCT00795210 Completed Massachusetts General Hospital 2012-11-30
NCT00028314 Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients https://ClinicalTrials.gov/show/NCT00028314 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00025883 Leptin to Treat Lipodystrophy https://ClinicalTrials.gov/show/NCT00025883 Completed National Institutes of Health Clinical Center (CC) 2015-02-28
NCT00021463 Changing to Nonprotease Inhibitor Treatment to Improve Side Effects https://ClinicalTrials.gov/show/NCT00021463 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2002-02-28
NCT00017758 The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs https://ClinicalTrials.gov/show/NCT00017758 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00015691 Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities https://ClinicalTrials.gov/show/NCT00015691 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2006-01-31
NCT00006412 Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids https://ClinicalTrials.gov/show/NCT00006412 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00005764 A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients https://ClinicalTrials.gov/show/NCT00005764 Completed NIH AIDS Clinical Trials Information Service NA
NCT00002417 A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications https://ClinicalTrials.gov/show/NCT00002417 Completed NIH AIDS Clinical Trials Information Service NA
NCT00005905 Leptin to Treat Lipodystrophy https://ClinicalTrials.gov/show/NCT00005905 Completed National Institutes of Health Clinical Center (CC) NA
NCT00006190 A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy https://ClinicalTrials.gov/show/NCT00006190 Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NA
NCT00006185 Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome https://ClinicalTrials.gov/show/NCT00006185 Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03826160 Growth Hormone Dynamics and Cardiac Steatosis in HIV https://ClinicalTrials.gov/show/NCT03826160 Recruiting Massachusetts General Hospital 2021-01-30
NCT03059121 The Cleveland Cardiometabolic Cohort https://ClinicalTrials.gov/show/NCT03059121 Recruiting University Hospitals Cleveland Medical Center 2021-08-31
NCT02614027 Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances https://ClinicalTrials.gov/show/NCT02614027 Completed Asociacion para el Estudio de las Enfermedades Infecciosas 2018-02-28
NCT02530827 Energy Expenditure of People Living With HIV/AIDS https://ClinicalTrials.gov/show/NCT02530827 Completed University of Sao Paulo General Hospital 2014-06-30
NCT02258685 Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. https://ClinicalTrials.gov/show/NCT02258685 Completed University of Colorado, Denver 2018-11-30
NCT01784289 Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity https://ClinicalTrials.gov/show/NCT01784289 Completed University Hospital, Lille 2015-06-30
NCT01359917 Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome https://ClinicalTrials.gov/show/NCT01359917 Completed NHS Lothian 2009-07-31
NCT03817840 Cushing’s Lipodystrophy https://ClinicalTrials.gov/show/NCT03817840 Recruiting Columbia University 2020-03-31
NCT01093950 White Light Scanning to Aid Body Contouring: A Pilot Project https://ClinicalTrials.gov/show/NCT01093950 Recruiting Eastern Virginia Medical School 2020-08-31
NCT00822042 Corticosteroid-induced Lipodystrophy and Adipokines https://ClinicalTrials.gov/show/NCT00822042 Completed Assistance Publique - Hôpitaux de Paris 2008-10-31
NCT00360932 Facial Lipoatrophy Correction Experience With SCULPTRA (“FACES” Study) https://ClinicalTrials.gov/show/NCT00360932 Completed Bausch Health Americas, Inc. 2011-08-31
NCT00225082 SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function https://ClinicalTrials.gov/show/NCT00225082 Completed Northwestern University 2006-12-31
NCT00149097 Role of the Autonomic Nervous System in HIV-Lipodystrophy https://ClinicalTrials.gov/show/NCT00149097 Completed Hannover Medical School NA
NCT00119405 Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) https://ClinicalTrials.gov/show/NCT00119405 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2010-11-30
NCT00069004 A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth https://ClinicalTrials.gov/show/NCT00069004 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00001142 Metabolism and Body Shape of Healthy Children and Children With Chronic Infections https://ClinicalTrials.gov/show/NCT00001142 Completed National Institutes of Health Clinical Center (CC) NA
NCT00006290 Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs https://ClinicalTrials.gov/show/NCT00006290 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00006064 The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children https://ClinicalTrials.gov/show/NCT00006064 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00004329 Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy https://ClinicalTrials.gov/show/NCT00004329 Completed National Center for Research Resources (NCRR) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03087253 The LD Lync Study - Natural History Study of Genetic Lipodystrophy Syndromes https://ClinicalTrials.gov/show/NCT03087253 Recruiting University of Michigan 2022-03-31
NCT03553420 Registry for Patients With Lipodystrophy https://ClinicalTrials.gov/show/NCT03553420 Recruiting University of Ulm 2068-01-31
NCT02577952 Lipodystrophy Connect Patient Registry https://ClinicalTrials.gov/show/NCT02577952 Completed PatientCrossroads 2018-11-08